The Top Five Most Viewed Content at Diagnostic Imaging in July 2023

For cT1 renal masses < 4 cm and renal masses < 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress.

Drs. Charles Liu and Jonathan Russin discuss the benefits and potential of fPACT, the alternative to functional MRI.

Review the case study and test your knowledge to make the correct diagnosis.

In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.

Over 80 percent of head and neck computed tomography angiography (CTA) exams performed in the emergency department had no actionable findings for patients with non-focal neurologic complaints, and 67 percent of the exams were ordered by non-physician practitioners (NPPs), according to a newly published study.

In a recent interview, Sophia Rose O’Brien, M.D., shared her insights on the roles and limitations of FDG PET/CT and FES PET/CT in the imaging of patients with metastatic breast cancer.